drugset / Trial / NCT01625403

Recombinant BNP on Heart and Renal Function in Acute Heart Failure

NCT01625403 ↗

Phase 2 Unknown 100 enrolled Shanghai Chest Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant human B-type natriuretic peptide (rhBNP) on heart and renal function in patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI).

Timeline

Start
2012-07
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject rhBNP Peptide 0.01 ug/kg Intravenous